Get the Stockscreener App
5.10
1.36%
-0.05
After Hours:
5.10
Precision Biosciences Inc stock is traded at $5.10, with a volume of 115.76K.
It is down -1.36% in the last 24 hours and up +18.14% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$5.15
Open:
$5.18
24h Volume:
115.76K
Relative Volume:
0.47
Market Cap:
$56.55M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-7.7273
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+9.25%
1M Performance:
+18.14%
6M Performance:
+0.79%
1Y Performance:
-49.70%
1-Day Range:
$5.02
$5.21
1-Week Range:
$4.58
$5.2499
52-Week Range:
$3.61
$11.09
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.10 | 57.10M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
What institutional investors are buying Precision BioSciences Inc. stockMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
What are analysts’ price targets for Precision BioSciences Inc. in the next 12 monthsInvest confidently with proven investment plans - jammulinksnews.com
What catalysts could drive Precision BioSciences Inc. stock higher in 2025Financial News Forecasts For Smart Trading - jammulinksnews.com
What are Precision BioSciences Inc. company’s key revenue driversBuild wealth steadily with expert advice - jammulinksnews.com
What are the technical indicators suggesting about Precision BioSciences Inc.Explosive capital appreciation - jammulinksnews.com
What is Precision BioSciences Inc. company’s growth strategyDiscover dynamic stocks ready to soar - jammulinksnews.com
Why Precision BioSciences Inc. stock attracts strong analyst attentionConsistent Win Signals - Metal.it
What drives Precision BioSciences Inc. stock priceDynamic investment opportunities - PrintWeekIndia
What analysts say about Precision BioSciences Inc. stockOver 200% growth - Autocar Professional
Precision BioSciences shares climb after FDA grants orphan drug status - MSN
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD - Contract Pharma
Precision Biosciences’ PBGENE-DMD gains US orphan drug designation - BioWorld MedTech
Precision BioSciences stock rises after FDA grants orphan drug status By Investing.com - Investing.com Canada
FDA Grants Orphan Drug Designation to Precision BioSciences' PBG - GuruFocus
FDA grants orphan drug status to Precision BioSciences’ DMD treatment - Investing.com Australia
FDA grants orphan drug status to Precision BioSciences’ DMD treatment By Investing.com - Investing.com South Africa
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
Precision BioSciences Inc. Stock Analysis and ForecastFree Capital Growth Strategies - jammulinksnews.com
Precision BioSciences Secures Orphan Drug Designation for DMD Treatment, DTIL Stock News - AInvest
Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status - TipRanks
Precision BioSciences gets FDA orphan drug designations for DMD treatment By Investing.com - Investing.com Canada
Precision BioSciences reports promising DMD gene editing results By Investing.com - Investing.com Canada
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
How Precision BioSciences Inc. stock performs during market volatilityFree Market Sentiment Analysis - Newser
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ - MSN
What makes Precision BioSciences Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
(DTIL) Proactive Strategies - news.stocktradersdaily.com
Precision Biosciences CFO Sells Shares to Cover Tax Obligations - TradingView
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to Russell 3000E Value Index - MarketScreener
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Director’s Bold Move: A Major Investment in Precision BioSciences - TipRanks
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):